Neurogenesis Platform
Multiple Neurological Disorders (Alzheimer's, Stroke, Depression, etc.)
Pre-clinicalActive
Key Facts
Indication
Multiple Neurological Disorders (Alzheimer's, Stroke, Depression, etc.)
Phase
Pre-clinical
Status
Active
Company
About Bolden Therapeutics
Bolden Therapeutics is an early-stage biotech focused on the challenging but high-potential field of therapeutic neurogenesis. The company has established preclinical proof-of-concept for its approach, demonstrating increased neurogenesis and enhanced memory in a proprietary mouse model. With a strong scientific foundation and a leadership team blending academic and venture expertise, Bolden is pursuing a multi-modality strategy against a broad range of neurological indications, including Alzheimer's disease, stroke recovery, and treatment-resistant depression. The company is currently in the pre-clinical development stage.
View full company profile